Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer
In Western industrialized countries, endometrial cancer is the most common malignancy of the female reproductive tract.

The general therapy options are surgery, radiotherapy, chemotherapy and endocrine therapy. This trial will investigate the efficacy and safety of letrozole in the treatment of advanced or recurrent hormone receptor-positive endometrial cancer .
Endometrial Cancer
DRUG: Letrozole
clinical response rate (partial response PR and complete response CR) according to RECIST at least once during the treatment period, until disease progression
Time to progression (TTP), until disease progression|Overall survival (OS), until disease progression
In Western industrialized countries, endometrial cancer is the most common malignancy of the female reproductive tract.

The general therapy options are surgery, radiotherapy, chemotherapy and endocrine therapy. This trial will investigate the efficacy and safety of letrozole in the treatment of advanced or recurrent hormone receptor-positive endometrial cancer .